Dihydrocodiene long termmuse

The short version: long-term dihydrocodeine use carries serious risks that are well-documented for the opioid class, but the evidence here does not include a single study on dihydrocodeine itself.

The evidence you see is about other opioids. A 2025 Swedish national study of 754,982 opioid-naïve adults found that 8.1% progressed to long-term use (over 3 months), with the odds of staying on for over a year rising sharply with age, lower education, and psychiatric history [5]. A 2017 neuropathy study of 545 patients on long-term opioids reported 9 cases of abuse and 14 overdoses, compared to 2 and 4 in the short-term group [1]. A 2003 case series in Chest documented severe sleep-disordered breathing in patients on sustained-release opioids, including central apneas and oxygen desaturation that CPAP could not fix [9].

None of these studies were funded by a manufacturer in a way that would bias the core finding. The 2025 Swedish study used national registry data, not industry money [5]. The neuropathy study was a retrospective cohort, not a trial [1]. The sleep study was a case series [9]. The evidence is observational, not from randomized trials, but the harms are consistent across different opioids, different populations, and different study designs.

What is missing is dihydrocodeine-specific data. No study here tests it directly. The opioid class effects are well enough established that you can expect the same risks: dependence, respiratory depression during sleep, constipation, cognitive impairment, and the possibility of hyperalgesia (opioids making pain worse over time). The 2025 Swedish study showed that primary-care initiation carried a 3-fold higher odds of long-term use compared to specialist prescribing [5], which matters because dihydrocodeine is often prescribed in primary care.

My call: the evidence for serious harm from long-term opioid use is consistent and comes from multiple independent sources, but none of it tests dihydrocodeine specifically. Confidence: moderate.